VERVE THERAPEUTICS INC (VERV) Stock Price & Overview
NASDAQ:VERV • US92539P1012
The current stock price of VERV is 11.13 USD. Today VERV is up by 0.27%. In the past month the price decreased by -0.71%. In the past year, price increased by 50.41%.
VERV Key Statistics
- Market Cap
- 992.128M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.11
- Dividend Yield
- N/A
VERV Stock Performance
VERV Stock Chart
VERV Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VERV. When comparing the yearly performance of all stocks, VERV is one of the better performing stocks in the market, outperforming 95.29% of all stocks.
VERV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VERV. While VERV has a great health rating, there are worries on its profitability.
VERV Earnings
On May 14, 2025 VERV reported an EPS of -0.35 and a revenue of 32.98M. The company beat EPS expectations (47.66% surprise) and beat revenue expectations (244.83% surprise).
VERV Forecast & Estimates
14 analysts have analysed VERV and the average price target is 13.26 USD. This implies a price increase of 19.14% is expected in the next year compared to the current price of 11.13.
For the next year, analysts expect an EPS growth of -8.2% and a revenue growth 93.9% for VERV
VERV Groups
Sector & Classification
VERV Financial Highlights
Over the last trailing twelve months VERV reported a non-GAAP Earnings per Share(EPS) of -2.11. The EPS increased by 26.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.47% | ||
| ROE | -38.23% | ||
| Debt/Equity | 0 |
VERV Ownership
VERV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.1 | 414.026B | ||
| AMGN | AMGEN INC | 16.73 | 207.692B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 186.139B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.26 | 123.316B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 83.604B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.57 | 42.945B | ||
| INSM | INSMED INC | N/A | 31.206B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.1 | 27.598B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.69 | 22.521B | ||
| MRNA | MODERNA INC | N/A | 20.646B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.138B | ||
| EXAS | EXACT SCIENCES CORP | 308.97 | 19.72B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VERV
Company Profile
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company is headquartered in Boston, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
Company Info
VERVE THERAPEUTICS INC
201 Brookline Avenue, Suite 601
Boston MASSACHUSETTS US
CEO: Sekar Kathiresan
Employees: 255
Phone: 19785013026
VERVE THERAPEUTICS INC / VERV FAQ
What does VERV do?
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company is headquartered in Boston, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
What is the stock price of VERVE THERAPEUTICS INC today?
The current stock price of VERV is 11.13 USD. The price increased by 0.27% in the last trading session.
Does VERVE THERAPEUTICS INC pay dividends?
VERV does not pay a dividend.
What is the ChartMill rating of VERVE THERAPEUTICS INC stock?
VERV has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting VERV stock to perform?
14 analysts have analysed VERV and the average price target is 13.26 USD. This implies a price increase of 19.14% is expected in the next year compared to the current price of 11.13.
What is the market capitalization of VERV stock?
VERVE THERAPEUTICS INC (VERV) has a market capitalization of 992.13M USD. This makes VERV a Small Cap stock.
Can you provide the ownership details for VERV stock?
You can find the ownership structure of VERVE THERAPEUTICS INC (VERV) on the Ownership tab.